Neurogene (NGNE) News Today $19.27 +0.02 (+0.10%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period 27,482 Shares in Neurogene Inc. $NGNE Bought by Nuveen LLCSeptember 8 at 3:19 AM | marketbeat.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | businesswire.comADAR1 Capital Management LLC Buys Shares of 27,925 Neurogene Inc. $NGNESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Has $17.40 Million Holdings in Neurogene Inc. $NGNESeptember 4, 2025 | marketbeat.comWalleye Capital LLC Has $1.10 Million Stock Position in Neurogene Inc. $NGNESeptember 2, 2025 | marketbeat.comEntryPoint Capital LLC Purchases New Position in Neurogene Inc. $NGNEAugust 27, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Moderate Buy" by BrokeragesAugust 24, 2025 | marketbeat.comWilliam Blair Issues Negative Outlook for Neurogene EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for Neurogene Q3 EarningsAugust 16, 2025 | marketbeat.comQ3 Earnings Estimate for Neurogene Issued By Leerink PartnrsAugust 16, 2025 | marketbeat.comNeurogene Advances NGN-401 Gene Therapy for Rett SyndromeAugust 14, 2025 | theglobeandmail.comNeurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPSAugust 12, 2025 | marketbeat.comNeurogene Inc. Reports Increased Losses Amid R&D FocusAugust 11, 2025 | tipranks.comNeurogene Reports Second Quarter 2025 Financial Results and Highlights Recent UpdatesAugust 11, 2025 | businesswire.comBlair William & Co. IL Increases Stock Position in Neurogene Inc. (NASDAQ:NGNE)August 10, 2025 | marketbeat.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | businesswire.comRaiffeisen Bank International AG Has $351,000 Stake in Neurogene Inc. (NASDAQ:NGNE)August 7, 2025 | marketbeat.comNeurogene (NGNE) to Release Earnings on FridayAugust 1, 2025 | marketbeat.comBullish Neurogene Insiders Loaded Up On US$1.46m Of StockJuly 30, 2025 | finance.yahoo.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 28, 2025 | marketbeat.comJennison Associates LLC Acquires 35,488 Shares of Neurogene Inc. (NASDAQ:NGNE)July 22, 2025 | marketbeat.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business WireJuly 5, 2025 | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | businesswire.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | marketbeat.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - MorningstarJuly 2, 2025 | morningstar.comMNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business WireJuly 2, 2025 | businesswire.comStifel maintient sa recommandation d’achat sur l’action NeurogeneJuly 2, 2025 | fr.investing.comLa FDA approuve le design d’essai clinique de Neurogene pour sa thérapie génique contre le syndrome de RettJune 30, 2025 | fr.investing.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett SyndromeJune 30, 2025 | businesswire.comCompanies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In GrowthJune 19, 2025 | finance.yahoo.comCraig-Hallum initiates Neurogene stock with buy rating on Rett therapyJune 18, 2025 | uk.investing.comCraig-Hallum bullish on Neurogene, initiates with a BuyJune 18, 2025 | finance.yahoo.comNeurogene (NASDAQ:NGNE) Coverage Initiated at Craig HallumJune 17, 2025 | marketbeat.comNeurogene (NGNE) Gets a Buy from BMO CapitalJune 14, 2025 | theglobeandmail.comNeurogene (NGNE) Gets a Buy from TD CowenJune 14, 2025 | theglobeandmail.comNeurogene price target raised to $26 from $22 at BMO CapitalJune 13, 2025 | investing.comNeurogene (NASDAQ:NGNE) Given New $26.00 Price Target at BMO Capital MarketsJune 12, 2025 | marketbeat.comL’objectif de prix de Neurogene relevé à 26€ contre 22€ par BMO CapitalJune 11, 2025 | fr.investing.comTwo Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE)June 10, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Moderate Buy" from BrokeragesJune 8, 2025 | marketbeat.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | businesswire.comSquarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE)June 6, 2025 | marketbeat.comNeurogene Reports Q1 2025 Financial Progress and UpdatesMay 30, 2025 | tipranks.comStifel maintient sa recommandation d’achat sur Neurogene avec un objectif de 46€May 29, 2025 | fr.investing.comDeutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE)May 23, 2025 | marketbeat.com80,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Vestal Point Capital LPMay 21, 2025 | marketbeat.comRaiffeisen Bank International AG Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $322,000 in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Rating Lowered by Baird R WMay 19, 2025 | marketbeat.com Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGNE Media Mentions By Week NGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼1.290.84▲Average Medical News Sentiment NGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼43▲NGNE Articles Average Week Get the Latest News and Ratings for NGNE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Neurogene and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MLYS News PHAR News NUVB News SYRE News CRON News ORIC News ATAI News PRAX News UPB News URGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredTime is running out on the most obvious trade in historyGold just broke out to fresh all-time highs, silver is up 40% this year, and for the first time in three decad...Golden Portfolio | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
